Design, immune responses and anti-tumor potential of an HPV16 E6E7 multi-epitope vaccine

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  De Oliveira, Liliane Maria Fernandes ^a   Morale, Mirian Galliote ^a   Chaves, Agatha A Muniz ^a   Cavalher, Aline Marques ^a   Lopes, Aline Soriano ^a   De Oliveira Diniz, Mariana ^b   Schanoski, Alessandra Soares ^a   De Melo, Robson Lopes ^a   De Souza Ferreira, Luís Carlos ^b   De Oliveira, Maria Leonor S ^a   Demasi, Marilene ^a   Ho, Paulo Lee ^a  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; E6E7 VACCINE; EPITOPE; GAMMA INTERFERON; PROTEIN E6; PROTEIN E7; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DESIGN; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; WILD TYPE; ALPHAPAPILLOMAVIRUS; AMINO ACID SEQUENCE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL LINE; CHEMISTRY; IMMUNOLOGY; KNOCKOUT MOUSE; MOLECULAR GENETICS; UTERINE CERVICAL NEOPLASMS;

ALPHAPAPILLOMAVIRUS; AMINO ACID SEQUENCE; ANIMALS; CANCER VACCINES; CELL LINE; EPITOPES; FEMALE; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; REPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 84946594838     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138686     Document Type: Article

References (46)

1. Ferlay J, Soerjomataram I, Diks hit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: E359-86. doi: 10.1002/ijc.29210 PMID: 25220842
2. Liu TY, Hussein WM, Toth I, Skwarczynski M. Advances in peptide-based human papillomavirus thera-peutic vaccines. Current topics in medicinal chemistry. 2012; 12: 1581-92. PMID: 22827526
3. Robinson WIII. Management of cervical neoplasia. Cancer treatment and research. 2001; 104: 287-302. PMID: 11227083
4. van der Burg SH. Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding. Expert review of vaccines. 2008; 7: 1-5. doi: 10.1586/14760584.7.1.1 PMID: 18251686
5. Diniz MO, Lasaro MO, Ertl HC, Ferreira LC. Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D. Clinical and vaccine immunology: CVI. 2010; 17: 1576-83. doi: 10.1128/CVI.00264-10 PMID: 20739505
6. Carpino LA, Han GY. 9-Fluorenylmethoxycarbonyl amino-protecting group. The Journal of Organic Chemistry. 1972; 37: 3404-9.
7. Ramos CR, Abreu PA, Nascimento AL, Ho PL. A high-copy T7 Escherichia coli expression vector for the production of recombinant proteins with a minimal N-terminal His-tagged fusion peptide. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas /Sociedade Brasileira de Biofisica [et al]. 2004; 37: 1103-9.
8. Comerford SA, McCance DJ, Dougan G, Tite JP. Identification of T-and B-cell epitopes of the E7 protein of human papillomavirus type 16. Journal of virology. 1991; 65: 4681-90. PMID: 1714516
9. Kast WM, Brandt RM, Sidney J, Drijfhout JW, Kubo RT, Grey HM, et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. Journal of immunology. 1994; 152: 3904-12.
10. Piersma SJ, Welters MJ, van der Hulst JM, Kloth JN, Kwappenberg KM, Trimbos BJ, et al. Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and-DP as a restriction element. International journal of cancer Journal international du cancer. 2008; 122: 486-94. PMID: 17955486
11. Ressing ME, de Jong JH, Brandt RM, Drijfhout JW, Benckhuijsen WE, Schreuder GM, et al. Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptidebased vaccination against cervical carcinoma. European journal of immunology. 1999; 29: 1292-303. PMID: 10229097
12. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A∗0201-binding peptides. Journal of immunology. 1995; 154: 5934-43.
13. Schreurs MW, Kueter EW, Scholten KB, Lemonnier FA, Meijer CJ, Hooijberg E. A single amino acid substitution improves the in vivo immunogenicity of the HPV16 oncoprotein E7(11-20) cytotoxic T lymphocyte epitope. Vaccine. 2005; 23: 4005-10. PMID: 15963358
14. Stauss HJ, Davies H, Sadovnikova E, Chain B, Horowitz N, Sinclair C. Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus. Proceedings of the National Academy of Sciences of the United States of America. 1992; 89: 7871-5. PMID: 1381502
15. Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. Journal of immunology. 2002; 169: 350-8.
16. Nakagawa M, Kim KH, Gillam TM, Moscicki AB. HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein. Journal of virology. 2007; 81: 1412-23. PMID: 17108051
17. Thomas KJ, Smith KL, Youde SJ, Evans M, Fiander AN, Borysiewicz LK, et al. HPV16 E6 29-38-specific T cells kill cervical carcinoma cells despite partial evasion of T-cell effector function. International journal of cancer Journal international du cancer. 2008; 122: 2791-9. doi: 10.1002/ijc.23475 PMID:18366058
18. Morishima S, Akatsuka Y, Nawa A, Kondo E, Kiyono T, Torikai H, et al. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope. International journal of cancer Journal international du cancer. 2007; 120: 594-604. PMID: 17096336
19. Nakagawa M, Kim KH, Moscicki AB. Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins. Clin Diagn Lab Immunol. 2004; 11: 889-96. PMID: 15358648
20. Smith KL, Tristram A, Gallagher KM, Fiander AN, Man S. Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. International immunology. 2005; 17: 167-76. PMID: 15623547
21. Gallagher KM, Man S. Identification of HLA-DR1-and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4+ T cells from healthy young women. J Gen Virol. 2007; 88: 1470-8. PMID: 17412975
22. van der Burg SH, Ressing ME, Kwappenberg KM, de Jong A, Straathof K, de Jong J, et al. Natural Thelper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. International journal of cancer Journal international du cancer. 2001; 91: 612-8. PMID: 11267969
23. Velders MP, Weijzen S, Eiben GL, Elmishad AG, Kloetzel PM, Higgins T, et al. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. Journal of immunology. 2001; 166: 5366-73.
24. Su JH, Wu A, Scotney E, Ma B, Monie A, Hung CF, et al. Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs. 2010; 24: 109-29. doi: 10.2165/11532810-000000000-00000 PMID: 20199126
25. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003; 421: 852-6. PMID: 12594515
26. Vambutas A, DeVoti J, Nouri M, Drijfhout JW, Lipford GB, Bonagura VR, et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine. 2005; 23: 5271-80. PMID: 16054734
27. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14: 169-77.
28. van der Burg SH, Kwappenberg KM, O'Neill T, Brandt RM, Melief CJ, Hickling JK, et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine. 2001; 19: 3652-60. PMID: 11395199
29. de Jong A, O'Neill T, Khan AY, Kwappenberg KM, Chisholm SE, Whittle NR, et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine. 2002; 20: 3456-64. PMID: 12297390
30. Gambhira R, Gravitt PE, Bossis I, Stern PL, Viscidi RP, Roden RB. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer research. 2006; 66: 11120-4. PMID: 17145854
31. Fiander AN, Tristram AJ, Davidson EJ, Tomlinson AE, Man S, Baldwin PJ, et al. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer. 2006; 16: 1075-81. PMID: 16803488
32. Wu CY, Monie A, Pang X, Hung CF, Wu TC. Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation. J Biomed Sci. 2010; 17: 88. doi: 10.1186/1423-0127-17-88 PMID: 21092195
33. Slingluff CL Jr. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J. 2011; 17: 343-50. doi: 10.1097/PPO.0b013e318233e5b2 PMID:21952285
34. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol. 2002; 2: 227-38. PMID: 12001994
35. Bergmann CC, Yao Q, Ho CK, Buckwold SL. Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes. J Immunol. 1996; 157: 3242-9. PMID: 8871618
36. Naylor PH, Egan JE, Berinstein NL. Peptide Based Vaccine Approaches for Cancer-A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen. Cancers (Basel). 2011; 3: 3991-4009.
37. Monroy-Garcia A, Gomez-Lim MA, Weiss-Steider B, Hernandez-Montes J, Huerta-Yepez S, Rangel-Santiago JF, et al. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model. Arch Virol. 2014; 159: 291-305. doi: 10.1007/s00705-013-1819-z PMID: 23990055
38. Hohn H, Pilch H, Gunzel S, Neukirch C, Hilmes C, Kaufmann A, et al. CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7. Journal of immunology. 1999; 163: 5715-22.
39. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. European journal of immunology. 1993; 23: 2242-9. PMID:7690326
40. Chen CH, Wang TL, Hung CF, Yang Y, Young RA, Pardoll DM, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer research. 2000; 60: 1035-42. PMID: 10706121
41. Granadillo M, Vallespi MG, Batte A, Mendoza O, Soria Y, Lugo VM, et al. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice. Vaccine. 2011; 29: 920-30. doi: 10.1016/j.vaccine.2010.11.083 PMID: 21145912
42. Freyschmidt EJ, Alonso A, Hartmann G, Gissmann L. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol. Antivir Ther. 2004; 9: 479-89. PMID: 15456078
43. Einstein MH, Kadish AS, Burk RD, Kim MY, Wadler S, Streicher H, et al. Heat shock fusion proteinbased immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol. 2007; 106: 453-60. PMID: 17586030
44. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, Mizzen LA. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol. 2000; 121: 216-25. PMID: 10931134
45. Peng S, Tomson TT, Trimble C, He L, Hung CF, Wu TC. A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther. 2006; 13: 257-65. PMID: 16177818
46. Diniz MO, Cariri FA, Aps LR, Ferreira LC. Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors. Hum Gene Ther. 2013; 24: 861-70. doi: 10.1089/hum.2013.102 PMID: 24007495